索拉非尼联合或不联合其他干预措施治疗肝细胞癌。
Sorafenib with or without co-interventions for hepatocellular carcinoma.
作者信息
Chen Shanshan, Liu Jian Ping, Li Xinyu, Dang Shoutao, Li Wei
机构信息
Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
出版信息
Cochrane Database Syst Rev. 2025 Jun 26;6(6):CD015851. doi: 10.1002/14651858.CD015851.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the beneficial and harmful effects of sorafenib, with or without co-interventions, versus placebo, no intervention, or the same co-interventions for adults, aged 18 and over, with hepatocellular carcinoma.
摘要
这是一项Cochrane系统评价（干预措施）的方案。目标如下：评估索拉非尼（无论是否联合其他干预措施）与安慰剂、不进行干预或相同的联合干预措施相比，对18岁及以上成年肝细胞癌患者的有益和有害影响。
相似文献
1
Sorafenib with or without co-interventions for hepatocellular carcinoma.
Cochrane Database Syst Rev. 2025 Jun 26;6(6):CD015851. doi: 10.1002/14651858.CD015851.
2
Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.
Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD011649. doi: 10.1002/14651858.CD011649.pub2.
3
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
4
Tamoxifen for adults with hepatocellular carcinoma.
Cochrane Database Syst Rev. 2024 Aug 12;8(8):CD014869. doi: 10.1002/14651858.CD014869.pub2.
5
Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.
Cochrane Database Syst Rev. 2015 Jan 26;1(1):CD006745. doi: 10.1002/14651858.CD006745.pub3.
6
Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma.
Cochrane Database Syst Rev. 2013 Dec 19;2013(12):CD003046. doi: 10.1002/14651858.CD003046.pub3.
7
Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011650. doi: 10.1002/14651858.CD011650.pub2.
8
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.
Lancet Gastroenterol Hepatol. 2025 Jul;10(7):658-670. doi: 10.1016/S2468-1253(25)00059-7. Epub 2025 May 20.
9
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.
JAMA Oncol. 2025 Feb 1;11(2):136-144. doi: 10.1001/jamaoncol.2024.5403.
10
Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
Hepatobiliary Pancreat Dis Int. 2012 Oct;11(5):458-66. doi: 10.1016/s1499-3872(12)60209-4.
本文引用的文献
1
Next-Generation Flexible Embolic Systems: Targeted Transarterial Chemoembolization Strategies for Hepatocellular Carcinoma.
Adv Mater. 2025 Jun;37(24):e2503971. doi: 10.1002/adma.202503971. Epub 2025 Apr 7.
2
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets.
Hepatol Int. 2025 Mar 29. doi: 10.1007/s12072-025-10799-2.
3
Combination locoregional and systemic therapies in hepatocellular carcinoma.
Lancet Gastroenterol Hepatol. 2025 Apr;10(4):369-386. doi: 10.1016/S2468-1253(24)00247-4. Epub 2025 Feb 21.
4
Cancer statistics, 2025.
CA Cancer J Clin. 2025 Jan-Feb;75(1):10-45. doi: 10.3322/caac.21871. Epub 2025 Jan 16.
5
Abscopal effect in a patient with advanced hepatocellular carcinoma upon resuming bevacizumab in combination with atezolizumab after radiotherapy.
Clin J Gastroenterol. 2024 Dec;17(6):1053-1057. doi: 10.1007/s12328-024-02030-w. Epub 2024 Aug 14.
6
Liver resection had better disease-free survival rates compared with radiofrequency ablation in hepatocellular carcinoma: a meta-analysis based on randomized clinical trials.
Int J Surg. 2024 Nov 1;110(11):7225-7233. doi: 10.1097/JS9.0000000000001943.
7
Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.
JAMA Oncol. 2024 Aug 1;10(8):1047-1054. doi: 10.1001/jamaoncol.2024.1831.
8
Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Clin Pharmacol Ther. 2024 Aug;116(2):328-345. doi: 10.1002/cpt.3312. Epub 2024 May 27.
9
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights.
JCO Oncol Pract. 2024 Aug;20(8):1035-1039. doi: 10.1200/OP.24.00189. Epub 2024 Apr 25.
10
Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors.
World J Gastroenterol. 2024 Mar 21;30(11):1533-1544. doi: 10.3748/wjg.v30.i11.1533.
Zotero 插件